The mutations of epidermal growth factor receptor (EGFR) kinase, the fusion of the anaplastic lymphoma kinase (ALK), and ROS Proto-Oncogene 1 Receptor Tyrosine Kinase (ROS1), result in an immense improvement in the remedy of sufferers with NSCLC [25–28]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.